OPM reports final results of its phase 1 study with RIPK2 inhibitor OPM-101

OPM reports final results of its phase 1 study with RIPK2 inhibitor OPM-101, with strong safety data and no cardiac toxicity, paving the way for the launch of phase 1b/2a

Dijon (France), October 22, 2024, at 6:00pm CEST– Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today confirms and details the final results of its Phase 1 clinical trial with OPM-101, its RIPK2 inhibitor and drug candidate administered orally to healthy volunteers (VS), first reported on July 16, 2024. This clinical trial began in February 2023, the database was frozen in June 2024, and the full results and final study report became available, as scheduled in the study timetable, in October 2024.